Kidney cancer screening: novel concepts beyond population-level screening

IF 21.8 1区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney international Pub Date : 2026-07-01 Epub Date: 2026-04-16 DOI:10.1016/j.kint.2026.02.039
Sabrina Helena Rossi , Hannah Harrison , Oliver Byass , Jessica Kitt , Michelle Clark , Kerrie Massey , Jason Pawluk , David Blunt , Stewart Manning , Grant D. Stewart
{"title":"Kidney cancer screening: novel concepts beyond population-level screening","authors":"Sabrina Helena Rossi ,&nbsp;Hannah Harrison ,&nbsp;Oliver Byass ,&nbsp;Jessica Kitt ,&nbsp;Michelle Clark ,&nbsp;Kerrie Massey ,&nbsp;Jason Pawluk ,&nbsp;David Blunt ,&nbsp;Stewart Manning ,&nbsp;Grant D. Stewart","doi":"10.1016/j.kint.2026.02.039","DOIUrl":null,"url":null,"abstract":"<div><div>Screening for kidney cancer has been identified as a research priority by several independent initiatives. Previous work revealed that the relatively low prevalence of kidney cancer in untargeted asymptomatic individuals hinders the cost-effectiveness and clinical utility of population screening. We, therefore, undertake a comprehensive literature review summarizing novel screening concepts beyond whole population screening, including targeting high-risk populations (to increase disease prevalence), screening for kidney cancer in combination with other abdominal conditions (to reduce costs), or combining both of these approaches. Risk-stratified screening may be undertaken using phenotypic and/or genetic risk scores. Phenotypic risk scores for kidney cancer generally achieve reasonable discrimination (area under the receiver operating characteristic curve between 0.67 and 0.71 in a mixed sex cohort), with the best performing model being based on age, sex, body mass index, smoking status, hypertension diagnosis, and systolic and diastolic blood pressure. Adding genetic to phenotypic data is costly and provides only a negligible gain in discrimination (an increase in the area under the receiver operating characteristic curve of 0.007 from 0.716 to 0.723), meaning it is unlikely to represent a clinically useful strategy. Alternatively, screening for kidney cancer may be combined with other conditions to maximize efficiency, including multicancer early detection tests and combined screening using ultrasonography (concurrently with abdominal aortic aneurysm screening) or abdominal computed tomography (concurrently with lung cancer screening). The latter strategy is most promising and has the highest public acceptability. In summary, we highlight benefits and harms of different screening strategies beyond traditional population screening and offer a comprehensive and contemporary summary of recent advances in this field and future research avenues.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 70-77"},"PeriodicalIF":21.8000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney international","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0085253826002516","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Screening for kidney cancer has been identified as a research priority by several independent initiatives. Previous work revealed that the relatively low prevalence of kidney cancer in untargeted asymptomatic individuals hinders the cost-effectiveness and clinical utility of population screening. We, therefore, undertake a comprehensive literature review summarizing novel screening concepts beyond whole population screening, including targeting high-risk populations (to increase disease prevalence), screening for kidney cancer in combination with other abdominal conditions (to reduce costs), or combining both of these approaches. Risk-stratified screening may be undertaken using phenotypic and/or genetic risk scores. Phenotypic risk scores for kidney cancer generally achieve reasonable discrimination (area under the receiver operating characteristic curve between 0.67 and 0.71 in a mixed sex cohort), with the best performing model being based on age, sex, body mass index, smoking status, hypertension diagnosis, and systolic and diastolic blood pressure. Adding genetic to phenotypic data is costly and provides only a negligible gain in discrimination (an increase in the area under the receiver operating characteristic curve of 0.007 from 0.716 to 0.723), meaning it is unlikely to represent a clinically useful strategy. Alternatively, screening for kidney cancer may be combined with other conditions to maximize efficiency, including multicancer early detection tests and combined screening using ultrasonography (concurrently with abdominal aortic aneurysm screening) or abdominal computed tomography (concurrently with lung cancer screening). The latter strategy is most promising and has the highest public acceptability. In summary, we highlight benefits and harms of different screening strategies beyond traditional population screening and offer a comprehensive and contemporary summary of recent advances in this field and future research avenues.
肾癌筛查——超越人群水平筛查的新概念。
筛查肾癌已被几个独立的倡议确定为研究重点。先前的研究表明,在非靶向无症状个体中相对较低的肾癌患病率阻碍了人群筛查的成本效益和临床效用。因此,我们进行了一项全面的文献综述,总结了除全人群筛查之外的新筛查概念,包括:针对高危人群(增加疾病患病率),筛查肾癌合并其他腹部疾病(降低成本),或将这两种方法结合起来。风险分层筛查可采用表型和/或遗传风险评分。肾癌的表型风险评分总体上实现了合理的区分(在混合性别队列中AUROC在0.67 ~ 0.71之间),其中基于年龄、性别、BMI、吸烟状况、高血压诊断、收缩压和舒张压的模型表现最好。将遗传数据添加到表型数据是昂贵的,并且只能提供可忽略的歧视增益(AUROC从0.716增加到0.723的0.007),这意味着它不太可能代表临床有用的策略。或者,肾癌筛查可与其他条件相结合,以最大限度地提高效率,包括:多癌早期检测试验、超声联合筛查(与腹主动脉瘤筛查同时进行)或腹部CT联合筛查(与肺癌筛查同时进行)。后一种策略最有希望,公众接受度最高。总之,我们强调了不同筛查策略在传统人群筛查之外的利弊,并对该领域的最新进展和未来的研究途径进行了全面和当代的总结。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Kidney international
Kidney international 医学-泌尿学与肾脏学
CiteScore
23.30
自引率
3.10%
发文量
490
审稿时长
3-6 weeks
期刊介绍: Kidney International (KI), the official journal of the International Society of Nephrology, is led by Dr. Pierre Ronco (Paris, France) and stands as one of nephrology's most cited and esteemed publications worldwide. KI provides exceptional benefits for both readers and authors, featuring highly cited original articles, focused reviews, cutting-edge imaging techniques, and lively discussions on controversial topics. The journal is dedicated to kidney research, serving researchers, clinical investigators, and practicing nephrologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书